Chemical Predictive Modelling and Natural Product‐based Divergent Synthesis – Design of Type B PPAPs with Nanomolar Activities against MRSA
Chemistry – A European Journal · 2024
DOI: 10.1002/chem.202401955 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2024. Verfasst von Philipp Peslalz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Chemistry and Food Chemistry, Technical University Dresden, Bergstr. 66, 01069, Dresden, Germany. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Quantitative Structure-Activity Relationship, Anti-Bacterial Agents, Biological Products. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg, Sächsisches Staatsministerium für Wissenschaft und Kunst, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
In response to the pressing global challenge of antibiotic resistance, time efficient design and synthesis of novel antibiotics are of immense need. Polycyclic polyprenylated acylphloroglucinols (PPAP) were previously reported to effectively combat a range of gram‐positive bacteria. Although the exact mode of action is still not clear, we conceptualized a late‐stage divergent synthesis approach to expand our natural product‐based PPAP library by 30 additional entities to perform SAR studies against methicillin‐resistant Staphylococcus aureus (MRSA). Although at this point only data from cellular assays are available and understanding of molecular drug‐target interactions are lacking, the experimental data were used to generate 3D‐QSAR models via an artificial intelligence training and to identify a common pharmacophore model. The experimentally validated QSAR model enabled the estimation of anti‐MRSA activities of a virtual compound library consisting of more than 100,000 in‐silico generated B PPAPs, out of which the 20 most promising candidates were synthesized. These novel PPAPs revealed significantly improved cellular activities against MRSA with growth inhibition down to concentrations less than 1 μm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Chemistry and Food Chemistry, Technical University Dresden, Bergstr. 66, 01069, Dresden, Germany.
- Interfaculty Institute of Microbiology and Infection Medicine Tübingen (IMIT), University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany.
- Cluster of Excellence Controlling Microbes to Fight Infections, University of Tübingen, Auf der Morgenstelle 28, 72076, Tübingen, Germany.
ORCID-Profile: Philipp Peslalz, Flavia Izzo, Heike Brötz-Oesterhelt, Friedrich Götz, Bernd Plietker
Förderung
- Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg
- Sächsisches Staatsministerium für Wissenschaft und Kunst
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Peslalz, P., Vorbach, A., Bleisch, A., Liberini, E., Kraus, F., Izzo, F., Brötz-Oesterhelt, H., Götz, F., & Plietker, B. (2024). Chemical Predictive Modelling and Natural Product‐based Divergent Synthesis – Design of Type B PPAPs with Nanomolar Activities against MRSA. Chemistry – A European Journal. https://doi.org/10.1002/chem.202401955
Vancouver
Peslalz P, Vorbach A, Bleisch A, Liberini E, Kraus F, Izzo F, et al. Chemical Predictive Modelling and Natural Product‐based Divergent Synthesis – Design of Type B PPAPs with Nanomolar Activities against MRSA. Chemistry – A European Journal. 2024. doi:10.1002/chem.202401955
BibTeX
@article{Peslalz2024,
author = {Peslalz, Philipp and Vorbach, Andreas and Bleisch, Anton and Liberini, Elisa and Kraus, Frank and Izzo, Flavia and Brötz-Oesterhelt, Heike and Götz, Friedrich and Plietker, Bernd},
title = {Chemical Predictive Modelling and Natural Product‐based Divergent Synthesis – Design of Type B PPAPs with Nanomolar Activities against MRSA},
journal = {Chemistry – A European Journal},
year = {2024},
doi = {10.1002/chem.202401955}
}
EUVIMED